Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM1 intratumoral injection combined with PD-(L)1 antibody in advanced solid tumors
ChiCTR2400081481Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Mar 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of KM1 in Nonhematologic neoplasms, Cervical Cancer (CC), endometrial cancer (EC) and 1 more (7 arms), sponsored by Union Hospital. Primary endpoints: Maximum tolerated dose, Recommended phase II dose and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
KM1
03
Conditions
Nonhematologic neoplasmsCervical Cancer (CC)endometrial cancer (EC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2400081481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081481.